Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?

To: Techplayer who wrote (8127)	10/20/2002 1:54:14 AM
From: Techplayer	Respond to of 57110

JNJ news: Johnson & Johnson (JNJ: news, chart, profile) faces a crucial meeting Tuesday of a Food and Drug Administration advisory panel, which is reviewing its drug-coated stents for keeping open clogged arteries. Analysts say approval of the potential $1 billion a year product is priced into the stock. See full story. Amgen (AMGN: news, chart, profile) late Friday won damages from an arbitrator's ruling in its attempt to prevent a Johnson & Johnson (JNJ: news, chart, profile) subsidiary, Ortho Biotech, from selling a blood medication, erythropoetin, in the U.S. In refusing a bid to halt a licensing agreement, the arbitrator awarded Amgen $150 million in damages, much less than the $1.2 billion Amgen sought. Johnson & Johnson said it will report the amount in its SEC-filed report as a third-quarter charge, cutting its previously announced EPS by 3 cents. But J&J said it reaffirms it full-year earnings outlook for $2.26 a share. See full story.